Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03082300
Recruitment Status : Terminated (Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.)
First Posted : March 17, 2017
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 12, 2017
Actual Study Completion Date : June 19, 2017